Amal Fawzy1, Karima M Sweify2, Hany M El-Fayoumy3, Nagwa Nofal2. 1. Department of clinical and Chemical Pathology, National Cancer Institute, Cairo University, Egypt. Electronic address: amalfawzy69@hotmail.com. 2. Department of Women's College for Arts, Science and Education, Ain Shams University, Egypt. 3. Department of Urology, Faculty of Medicine Kasr Al-Ainy, Cairo University, Egypt.
Abstract
BACKGROUND: Prostate cancer (PC) is the most common cancer affecting men, it accounts for 29% of all male cancer and 11% of all male cancer related death. DNA is normally released from an apoptotic source which generates small fragments of cell-free DNA, whereas cancer patients have cell-free circulating DNA that originated from necrosis, autophagy, or mitotic catastrophe, which produce large fragments. AIM OF WORK: Differentiate the cell free DNA levels (cfDNA) and its integrity in prostate cancer patients and control group composed of benign prostate hyperplasia (BPH) and healthy persons. METHODOLOGY: cf-DNA levels were quantified by real-time PCR amplification in prostate cancer patients (n= 50), (BPH) benign prostate hyperplasia (n= 25) and healthy controls (n= 30) using two sets of ALU gene (product size of 115bp and 247-bp) and its integrity was calculated as a ratio of qPCR results of 247bp ALU over 115bp ALU. RESULTS: Highly significant levels of cf-DNA and its integrity in PC patients compared to BPH. Twenty-eight (56%) patients with prostate cancer had bone metastasis. ALU115 qpcr is superior to the other markers in discriminating metastatic patients with a sensitivity of 96.4% and a specificity of 86.4% and (AUC=0.981) CONCLUSION: ALU115 qpcr could be used as a valuable biomarker helping in identifying high risk patients, indicating early spread of tumor cells as a potential seed for future metastases.
BACKGROUND:Prostate cancer (PC) is the most common cancer affecting men, it accounts for 29% of all male cancer and 11% of all male cancer related death. DNA is normally released from an apoptotic source which generates small fragments of cell-free DNA, whereas cancerpatients have cell-free circulating DNA that originated from necrosis, autophagy, or mitotic catastrophe, which produce large fragments. AIM OF WORK: Differentiate the cell free DNA levels (cfDNA) and its integrity in prostate cancerpatients and control group composed of benign prostate hyperplasia (BPH) and healthy persons. METHODOLOGY: cf-DNA levels were quantified by real-time PCR amplification in prostate cancerpatients (n= 50), (BPH) benign prostate hyperplasia (n= 25) and healthy controls (n= 30) using two sets of ALU gene (product size of 115bp and 247-bp) and its integrity was calculated as a ratio of qPCR results of 247bp ALU over 115bp ALU. RESULTS: Highly significant levels of cf-DNA and its integrity in PC patients compared to BPH. Twenty-eight (56%) patients with prostate cancer had bone metastasis. ALU115 qpcr is superior to the other markers in discriminating metastatic patients with a sensitivity of 96.4% and a specificity of 86.4% and (AUC=0.981) CONCLUSION: ALU115 qpcr could be used as a valuable biomarker helping in identifying high risk patients, indicating early spread of tumor cells as a potential seed for future metastases.
Authors: Esther Campos-Fernández; Letícia S Barcelos; Aline Gomes de Souza; Luiz R Goulart; Vivian Alonso-Goulart Journal: Am J Cancer Res Date: 2019-07-01 Impact factor: 6.166
Authors: Jacob E Till; Taylor A Black; Caren Gentile; Aseel Abdalla; Zhuoyang Wang; Hareena K Sangha; Jacquelyn J Roth; Robyn Sussman; Stephanie S Yee; Mark H O'Hara; Jeffrey C Thompson; Charu Aggarwal; Wei-Ting Hwang; Kojo S J Elenitoba-Johnson; Erica L Carpenter Journal: J Mol Diagn Date: 2021-08-25 Impact factor: 5.341
Authors: Zijian Yang; Michael J LaRiviere; Jina Ko; Jacob E Till; Theresa Christensen; Stephanie S Yee; Taylor A Black; Kyle Tien; Andrew Lin; Hanfei Shen; Neha Bhagwat; Daniel Herman; Andrew Adallah; Mark H O'Hara; Charles M Vollmer; Bryson W Katona; Ben Z Stanger; David Issadore; Erica L Carpenter Journal: Clin Cancer Res Date: 2020-04-16 Impact factor: 12.531
Authors: Stephen J Bagley; S Ali Nabavizadeh; Jazmine J Mays; Jacob E Till; Jeffrey B Ware; Scott Levy; Whitney Sarchiapone; Jasmin Hussain; Timothy Prior; Samantha Guiry; Theresa Christensen; Stephanie S Yee; MacLean P Nasrallah; Jennifer J D Morrissette; Zev A Binder; Donald M O'Rourke; Andrew J Cucchiara; Steven Brem; Arati S Desai; Erica L Carpenter Journal: Clin Cancer Res Date: 2019-10-30 Impact factor: 12.531